Evaxion A (EVAX) Income from Continuing Operations (2020 - 2026)
Evaxion A (EVAX) posted Income from Continuing Operations of 4061000.0 for Q1 2026, up 36.83% on a QoQ basis from 6429000.0 in Q4 2025, and down 106.77% year-over-year from 59968451.13 in Q1 2025.
Evaxion A (EVAX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Evaxion A's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 4061000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 106.77% year-over-year to 4061000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11624000.0 (up 21.81% YoY) and the FY2025 annual result came in at 9523000.0, up 21.58% from the prior year.
- Income from Continuing Operations was 4061000.0 for Q1 2026 at Evaxion A, up from 6429000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 4087000.0 in Q3 2025 and bottomed at 7218000.0 in Q4 2022.
- A 5-year average of 3817823.53 and a median of 4877000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations tumbled 2818.58% — and 2025, when it surged 292.15%.
- Evaxion A's Income from Continuing Operations stood at 7218000.0 in 2022, then surged by 32.43% to 4877000.0 in 2023, then increased by 14.31% to 4179000.0 in 2024, then sank by 53.84% to 6429000.0 in 2025, then jumped by 36.83% to 4061000.0 in 2026.
- Business Quant data shows EVAX's Income from Continuing Operations at 4061000.0 in Q1 2026, 6429000.0 in Q4 2025, and 4087000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Evaxion A | 1.23 Bn | 1.23 Bn | - | -4.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.06 Mn |
| Dec 31, 2025 | -6.43 Mn |
| Sep 30, 2025 | 4.09 Mn |
| Jun 30, 2025 | -5.22 Mn |
| Mar 31, 2025 | -1.96 Mn |
| Dec 31, 2024 | -4.18 Mn |
| Sep 30, 2024 | -2.13 Mn |
| Jun 30, 2024 | -6.60 Mn |
| Mar 31, 2024 | 758,000.00 |
| Dec 31, 2023 | -4.88 Mn |
| Sep 30, 2023 | -6.07 Mn |
| Jun 30, 2023 | -226,000.00 |
| Mar 31, 2023 | -6.63 Mn |
| Dec 31, 2022 | -7.22 Mn |
| Sep 30, 2022 | -6.09 Mn |
| Jun 30, 2022 | -1.78 Mn |
| Mar 31, 2022 | -6.29 Mn |
| Dec 31, 2021 | -5.72 Mn |
| Sep 30, 2021 | -19.16 Mn |
| Jun 30, 2021 | -653,000.00 |